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Detection of circulating tumor cells (CTCs) in the blood via so-called “liquid biopsies”
carries enormous clinical potential in malignancies of the central nervous system (CNS)
because of the potential to follow disease evolution with a blood test, without the
need for repeat neurosurgical procedures with their inherent risk of patient morbidity.
To date, studies in non-CNS malignancies, particularly in breast cancer, show increasing
reproducibility of detection methods for these rare tumor cells in the circulation. However,
nomethod has yet received full recommendation to use in clinical practice, in part because
of lack of a sufficient evidence base regarding clinical utility. In CNS malignancies, one of
the main challenges is finding a suitable biomarker for identification of these cells, because
automated systems, such as the widely used Cell Search system, are reliant on markers,
such as the epithelial cell adhesion molecule, which are not present in CNS tumors. This
review examines methods for CTC enrichment and detection, and reviews the progress
in non-CNS tumors and the potential for using this technique in human brain tumors.
Keywords: circulating tumor cells, glioblastoma multiforme, glioma, liquid biopsy, epithelial–mesenchymal
transition
Introduction
Detection of circulating tumor cells (CTCs) is of current great interest in central nervous system
(CNS) malignancies because of recent intriguing reports, suggesting that cells from a proportion
of patients with glioblastoma multiforme (GBM) may be detectable in the bloodstream (1–3).
Outwit the CNS field, detection of CTCs represents a promising non-invasive technique to facilitate
early diagnosis and monitoring tumor biology evolution, which is underlined by over 500 studies,
registered internationally involving CTCs (4–6). The potential of the CTC approach was highlighted
in an early study by Ross et al. who described peripheral blood contamination by free floating cells of
Abbreviations: BBB, blood–brain barrier; CNS, central nervous system; CTC, circulating tumor cells; ctDNA, circulating
tumor DNA; DAPI, 40,6-diamidino-2-phenylindole; DTCs, disseminated tumor cells; EMT, epithelial–mesenchymal transi-
tion; EpCAM, epithelial cell adhesionmolecule; FISH, fluorescent in situ hybridization; GBM, glioblastomamultiforme; GFAP,
glial fibrillary acidic protein; hGBM, primary glioblastoma multiforme cells; IF, immunofluorescence; IHC, immunohisto-
chemistry; ISH, in situ hybridization; MNC, mononuclear cells; OS, overall survival; PCR, polymerase chain reaction; PFS,
progression-free survival; QPCR, quantitative PCR; RT-PCR, real-time PCR.
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metastatic breast cancer in patients receiving autologous stem
cell transplants (7). Due to the scarcity of CTCs in the blood
the interest in this field initially shifted to enhancement of cell
detection and identification using techniques, such as immuno-
magnetic labeling followed by polymerase chain reaction (PCR)
(8, 9). RT-PCR and qPCR are widely used today as standards
of CTC identification (10) although both methods are highly
sensitive and suffer from a false positive rate due to the presence
of contaminating cells (9).
Circulating tumor cells have now been described in most com-
mon carcinomas including breast, prostate, and colorectal carci-
noma (11, 12), and most recently in CNS malignancies (13–17).
There is evidence that CTC count has prognostic validity in breast
cancer (18) and in particular has been related to progression-free
survival (PFS) and overall survival (OS) in patientswithmetastatic
disease (19).
At present, the only CTC detection platform to receive valida-
tion by the Food and Drug Administration of the United States
of America is the CellSearch® system (Veridex, Raritan, NJ, USA)
(20), which is a robust platform but not without its limitations,
discussed further in this review. Currently, more advanced meth-
ods, e.g., CTC-chip and the EPISPOT allow isolation of still viable
tumor cells enabling more detailed analysis (21, 22).
Expanding research in this field has uncovered biological
dynamics of CTCs along the metastatic pathway (23) and uncov-
ered tumor subtypes namely stem cells and disseminated tumor
cells (DTCs) (24). DTCs are a CTC subpopulation found in bone
marrowwhichmay act as a dormant reservoir ofmalignant disease
(4, 25, 26) and it is suggested that their prognostic value might be
equal to CTCs (4, 24). A study by Baccelli et al. suggested a sub-
population of CTCs displaying CD44 cancer stem cell and bone
homing marker, CD47, which inhibits phagocytosis and MET (a
hepatocyte growth factor receptor); these have been postulated to
reflect the promotion of metastatic and invasive activity (27).
Dissemination of Malignancy
Initial stages of potential metastatic tumor spread begin with a
heterogenous population of malignant cells where the dynamic
changes in the tumor cell genome may give rise to metastasis
induction, followed by progression and virulence (28). The devel-
opment of metastatic disease has been divided into several stages,
each characterized by specific genomic, epigenomic, and pheno-
typic alterations: persistence of proliferation-promoting signals,
evasion of growth suppressors, resistance to cell death enabling
replicative immortality, promotion of angiogenesis, and initia-
tion of the invasive and metastatic process (29). Studies have
demonstrated that as few as 0.01% of circulating cancer cells
develop into secondary tumors with oxygenation, pH, nutrient
supply, and inflammatory response constantly influencing this
process (28). It is now thought that in order to enter the circula-
tion, epithelial tumor cells may undergo epithelial–mesenchymal
transition (EMT) (30). Primary epithelial malignant cells may
putatively undergo transdifferentiation to a mesenchymal geno-
type with intermediate epithelial–mesenchymal forms present (4,
23, 25, 26, 30, 31). Furthermore, it has been postulated that
to exit the circulatory system, CTCs may in fact undergo a
“reverse” mesenchymal–epithelial transition (4), suggesting that
the most effective CTCs are probably of an intermediate phe-
notype. EMT is thought to have an origin in embryogenesis
when bulk migration of developing cells occurs through compact
tissue stroma and there may be upregulation of many factors
including (TGFβ), WNT, platelet-derived growth factor (PDGF),
and interleukin-6 (IL-6) (30). While cells undergo EMT they
gradually lose their epithelial markers, i.e., E-cadherin, claudin,
and plakoglobin (23, 30) and acquire mesenchymal markers,
such as fibronectin, cadherin 2, and serine proteinase inhibitor-1
(SERPIN 1) (32).
More recent evidence suggests that in addition to single CTCs,
tumor fragments are also represented in the blood as microem-
boli containing stromal fibroblasts, leukocytes, and platelets (33)
creating a “floating” microenvironment. These micro-fragments
have been shown to evade anoikis and elimination by the immune
system in the bloodstream (30, 33, 34) and promote adhe-
sion and tissue invasion at secondary sites (30, 33, 35). Uppal
et al. explored this mechanism by showing that aspirin may
disrupt adherence of tumor microemboli at distant tissues (36).
CTCs are relatively rare with approximately 1 CTC per 105–108
white blood cells (26). CTCs are phenotypically thought to be
a heterogeneous population, each cell showing variable expres-
sion of biomarkers (37). However, the epithelial cell adhesion
molecule (EpCAM) is a 30–40 kDa transmembrane glycopro-
tein commonly expressed not only on epithelioid CTCs but
also on a proportion of white cells (38). It has become the
target molecule for cell selection and enumeration of various
detection systems primarily focused on epithelial malignancies
(20, 21, 39–45).
In an optimal theoreticalmodel, CTCs should express biomark-
ers not detected on other intrinsic cells in the bloodstream and not
lost in the mesenchymal and circulating cell transition (46). They
can be divided according to their function into prognostic, phar-
macodynamic, predictive, surrogate, and monitoring biomarkers
(5). The extracted cell should remain viable to allow post hoc
molecular analysis (4, 46) and acquisition of good quality DNA
rich material assures more efficient molecular identification of
cells (47).
CTC Enrichment and Detection
Numerous techniques of CTC identification can be divided into
broad groups according to methods of cell enrichment and cell
detection, which can be used in various combinations (26, 33,
48). The most commonly shared principles of enrichment are
antibody mediated or physical methods followed by secondary
immunohistochemical enumeration and/or subsequent genetic
analysis (33).
The CellSearch® platform utilizes EpCAM labeled CTC enrich-
ment using antibody-coated magnetic beads and labeling with
fluorescent-coated antibodies against cytokeratin together with
40,6-diamidino-2-phenylindole (DAPI) nuclear coating (19, 20).
Althoughwidely used, it is recognized that EpCAM-based enrich-
ment suffers from limitations, such as relatively low sensitivity and
purity, partly due to the presence of EpCAM negative tumor cells
(38, 49). For example, cells expressing CD45+ EpCAM+ were
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demonstrated to represent a macrophage population that may be
a source of false positivity (50).
Enrichment selectionmethods using the anti-EpCAMantibody
have been evolving through the introduction ofmicrofluidic chips
(CTC-chip, CTC-iChip®, Herringbone Chip, etc.) and of varia-
tions to known immunomagnetic and flow cytometry techniques
(39, 45). Novel models have described the use of an antibody-
coated intravenous wire, which is inserted directly into a vein
(40). By directly exposing the probe to a constant large-volume
flow of blood this method increases the probability of capturing
CTC thereby addressing the issue of their very low concentration.
Fisher et al. incorporated leukapheresis together with CellSearch®
to address this issue (51). A variety of physical property-based
enrichment methods have also been introduced, such as dielec-
trophoretic field flow fractionation (DEP-FFF) (52), ISET® (53),
or Dean flow fractionation (54), some of which may allow cell
culture of retrieved CTCs.
Figure 1 presents the most commonly described methods of
CTC enrichment and detection. A standard 7.5–10ml blood sam-
ple is processed within 2 h of withdrawal. Biological enrichment
incorporates anti-epithelial, leukocytic, or mesenchymal antibod-
ies labeled by a magnetic particle or affixed to a post or a rod (20,
39, 55). Positive enrichment relies on selective capture of CTCs,
while negative enrichment through labeling of CD45 filters out
cells which express leukocytic markers (22).
Modified immunomagnetic methods can achieve high degree
of CTCpurification and to allow downstream analysis, while some
techniques preclude cell culture of retrieved CTCs. Combina-
tion of techniques, such as MoFloXDP cell sorting, with qPCR
allows high-throughput analysis through single cell-array based
comparative genomic hybridization (56, 57). In a related method,
the AdnaTest utilizes double EMA and EpCAM magnetic bead
enrichment followed by RT-PCR multigene panel (56). Microflu-
idic on-chipmethods have been developed offering a single device
solution and efficient analysis pairing immunomagnetic enrich-
ment with IHC or PCR (21, 41–43, 58). Certain chips offer single
cell high-throughput analysis through physical enrichment tak-
ing advantage of cell size and deformity, again with biological
properties preserved (59). Others combine filter-based methods
with on-filter immunofluorescence (60). The micro-Hall detector
(µHD) chip enriches CTCs with immunomagnetic nanoparti-
cles allowing up to 107 cell/min analysis preserving antigeneity
permitting the use of bespoke imunoprofiles (61). An additional
advantage of this approach is the ability to analyze unpurified sam-
ples which reduces processing time (61). A different nanoparticle
method uses gold particles with single strand DNA, which bind to
intracellular mRNA in live cells. The entry of nanoparticles into
cells does not induce cell death preserving the isolated CTCs for
downstream phenotyping (62).
Apart from CTCs, circulating tumor DNA (ctDNA) fragments
offer an attractive quantification tool through digital PCR assay
and targeted deep sequencing (63), which is based on the sam-
ples obtained from 30 patients with metastatic breast cancer.
Dawson et al. found ctDNA to be of superior prognostic value
FIGURE 1 | Row (A) demonstrates methods of biological CTC
enrichment using magnetically labeled antibodies captured in a
magnetic chamber or by posts or rods. Row (B) illustrates physical
enrichment methods: membrane filtration, microfluidics, Ficoll gradient
centrifugation, Dean drag forces separation, and dielectrophoresis. Row
(C) outlines the most common principles of cell enumeration: IHC, RT-PCR,
fluorescent antibody labeling, invasion assay, or antibody-coated beads. Based
on Alix-Panabieres and Pantel (46) with permission.
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to Ca15.3 and CTCs (63). However, the biological properties
of CTCs have the potential of specific tumor phenotyping (63).
Investigation into other uses, such as diagnosis of malignancies
of unknown primaries, offers another interesting potential use of
this methodology (64).
CTCs as Predictors of Survival
in Non-CNS Malignancies
In 2007, the American Society of Clinical Oncology issued treat-
ment guidelines, which did not recommend routine detection of
CTCs in breast cancer patients in part due to a lack of evidence
base as to their prognostic utility (65). However, numerous publi-
cations includingmeta-analyses have emerged sincewhichmay be
addressed in updated guidelines. Following a recent international
multi center study, there is now substantial evidence that detection
of five or more CTCs in the blood of breast cancer patients leads
to decreased OS and PFS at different stages of follow-up (66).
A recent meta-analysis by Zhang et al. found that CellSearch®
enrichment combined with RT-PCR was superior in predicting
PFS, while prediction of OS was similar regardless of the methods
used (67). Prediction of OS was most significant when CTCs were
measured at cancer baseline compared with other stages of disease
(67). CTCs have been found in patients in all clinical stages includ-
ing patients with T1 and T2 operable disease regardless of tumor
stage, grade, lymph node, or receptor status (68). Some authors
suggested a single detectedCTCcarries higher disease progression
risk in non-metastatic chemosensitive (69) and locally advanced
(70) breast cancer. Furthermore, in a related study by Pierga et al.
showed predictive significance even if detected at a rate of 1
CTCs (71).
Presently, ongoing trials are focusing on particular stages of
treatment and analyze methods of CTC detection in metastatic
breast cancer (CTC-EMT, CTC-CEC-AND), provide input on
clinical aspect relating to cost-effectiveness (STIC CTC), and
evaluate patients at specific clinical points providing informa-
tion on prognostication and treatment guidance (Detect III,
CirCe01, Treat CTC, COMETI P2) (25). In aggressive triple neg-
ative cancers, baseline and early follow-up measurement of CTCs
identifies groups of patients with higher tumor chemoresistance
(TBCRC 019) (72).
The LANDSCAPE trial investigated patients with metastatic
disease to the brain comparing CTC levels before treatment
and after lapatinib and capecitabine at 3weeks in Her2 positive
tumors (71). The results were compared with levels of soluble
serum biomarkers. The authors found CTCs predict treatment
response more accurately avoiding post treatment biomarker
spike (71). Interestingly, CTCs occurred less frequently in patients
with isolated brain metastases presumably due to properties of
the blood–brain barrier (71, 73). Metastatic breast cancer cells
variably express EpCAM but may have a more distinct phe-
notype HER2+/EGFR+/HPSE+/Notch1+ (74). An additional,
potentially useful marker, aldehyde dehydrogenase 1 (ALDH1),
is of interest as cells lacking this enzyme are unable to form
tumors (75).
Second to breast, CTCs have been commonly utilized in
prostate carcinoma with the same CTC cut-off of five or more
CTCs found to be correlating significantly with prognosis (76).
The predictive value of CTCs was described in castration resis-
tant prostate cancer following prostate-specific antigen (PSA) and
lactate dehydrogenase (LDH) serum levels (77). Although the
CellSearch® system appears to be the method of choice in prostate
cancer, more specific markersmay be necessary, such as cadherin-
11, which is expressed not only on prostate cells and osteoblasts
but also on prostate cancer cells exhibiting EMT (78).
Colorectal cancer CTCs traverse the portal circulation with a
proportion of the cells being filtered by the liver (79). In colorectal
cancer, a value of 3 CTCs or above has commonly been used (80).
A large study from the USA showed an independent prognostic
effect of CTC counts regardless of serum carcinoembryonic anti-
gen (CEA) levels (81). However, measurement of CTCs prior to
resection of liver metastases does not appear to show prognostic
effect (82). Colorectal CTCs have been demonstrated to show
similar KRAS and BRAF gene status to the primary tumor with
68–100% concordance (5, 83). This may allow identification of
patients more likely to be resistant to EGFR inhibitors, but meth-
ods of more effective enrichment are required to prevent false
negative mutation results (83).
Several studies emergedwhich confirmed the presence of CTCs
in both small cell and non-small cell lung carcinomas. Hou et al.
found 85%of patientswith confirmed cancer had detectable circu-
lating cells at baseline (84). These authors also devised a bespoke
method of establishing the best predictive CTC cut-off, arguing
that the values should vary according to individual biological
properties of cancers (84). Lung cancer CTCs were also shown to
be suitable for EGFR receptor status analysis (85).
To date, CTCs have also been confirmed in ovarian, esophageal,
urothelial, pancreatic, head and neck (13–17) carcinomas using a
mixture of CellSearch® platform paired with PCR or microfluidic
technologies. CTC thresholds range from 1 to 5 CTCs as cut-off
but studies are conducted on small groups and require validation.
Potential Value of CTCs in CNS
Despite the fact that systemic metastases are rare in GBM, a few
recent studies have successfully isolated CTCs from peripheral
blood of both primary and recurrent adult GBM and diffuse
glioma, which could yield great potential for diseasemonitoring to
guide treatment (seeTable 1). A key issue is finding an appropriate
CNS biomarker to identify the CTCs, because CNS malignancies
do not express EpCAM, unlike many epithelial malignancies,
which commonly metastasize (3, 86). In a large study by Müller
et al., CTCs were identified in 29/141 (20.6%) of GBM patients
using physical separation methods (Ficoll gradient) followed by
immunostaining for glial fibrillary acidic protein (GFAP) (3). In
this case, the use of GFAP for CTC identification was supported
by its absence in control participants, and the presence of EGFR
amplifications in the tumor cells isolated using GFAP (3). The
mobilization of CTCs into the peripheral blood, which still main-
tains EGFR amplifications supports the hypothesis that they do
maintain growth potential (3).
Moreover, authors fromMassachusetts Institute of Technology
recently published a set of biomarkers found on CTCs with the
use of a CTC-iChip® (87). The STEAM panel consisted of sex
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TABLE 1 | Summary of studies attempting to isolate CTCs from patients with high-grade gliomas.
Author Cell enrichment Cell characterization Results Limitations
PUBLICATIONS POSITIVELY IDENTIFYING CTCs IN BRAIN TUMOR PATIENTS
Müller et al.
(3)
MNCs isolated by Ficoll density
gradient centrifugation
GBM patients n= 29/141 Low detection rate
Cytospins prepared from MNCs
GFAP positive single cells
isolated by micromanipulation
Chromogenic and fluorescent IHC
(GFAP, CD45, EGFR)
Observed association between
EGFR amplification and release
of CTCs
Common genomic aberrations in
CTCs and GBM tumors
Further characterization of CTCs and
associated tumor
Comparative genomic hybridization
Sequence analysis
FISH
Sullivan et al.
(87)
Blood processed through a
CTC-iChip® (magnetically tagged
CD45 and CD16)
GBM patients n= 26/87 Limited dataset
IF-guided single-cell
micromanipulation used to
isolate single CTCs (EGFR, MET
and CDH11)
IHC glioma marker panel [SOX2,
Tubulin, beta-3, EGFR, A2B5 and
c-MET (STEAM)]
RNA-ISH demonstrated an
enrichment for mesenchymal
transcripts and a reduction of
neural differentiation markers
Could not determine whether
surgical or radiation induced
disruption of the blood–brain
barrier enhances CTC
dissemination
FISH used to determine EGFR gene
amplification in CTCs from known
amplified cases
Further CTC characterization by
qRT-PCR and dual color RNA-ISH
assay
MacArthur
et al. (88)
Blood samples centrifuged in
OncoQuick tubes
High-grade glioma patients n= 8/11 pre-radiotherapy Limited pilot data
Incubated with a telomerase-responsive
adenoviral probe (via GFP expression)
Secondary Immunofluorescence (Nestin
and EGFR)
n= 1/8 post-radiotherapy Need more serial measurements
throughout the treatment and
disease course for each patient
EGFR amplification in CTCs
correlates with solid tumors
Telomerase is elevated in other
tumor histologies
PUBLICATIONS NEGATIVELY IDENTIFYING CTCs IN BRAIN TUMOR PATIENTS
Böhm et al.
(89)
Total cellular RNA extracted from
whole blood using the QIAmp
RNA blood mini kit (Qiagen)
High-grade astrocytoma and GBM
patients
n= 0/20 Sample size
RT-qPCR assay for the detection of
mRNA encoding GFAP and B2M
(positive control)
Insufficient technology
Martens
et al. (90)
Cytocentrifugation Astrocytoma patient n= 0/1 Only one patient and sample
tested
Chromogenic and fluorescent IHC
(GFAP)
Insufficient technology
determining region Y-box 2 (SOX2), tubulin beta-3, EGFR, A2B5,
and c-Met and found specifically on high-grade glioma cells (87).
Circulating glioma tumor cells were found to harbor elevated
SERPINE1, TGFB1, TGFBR2, and vimentin, which are associated
with an aggressive mesenchymal phenotype (87). The authors
suggest that there may be a subset of mesenchymal cells present
in disseminated GBM that have the ability to invade the vascular
system and proliferate outside the brain as systemic lesions (87).
An interesting approach used in the pilot study by MacArthur
et al. identified CTCs with an adenoviral telomerase-responsive
probe that consisted of the expression cassette for green fluo-
rescent protein (GFP) as well as the hTERT promoter driving
expression of E1A and E1B for viral replication and amplification
of the GFP signal that can detect the increased telomerase activity
in the CTCs following physical separation with OncoQuick tubes
(88). This was combined with immunofluorescence for GFAP and
nestin which helped to delineate the glial origin of the CTCs (88).
The MacArthur study identified circulating glioma cells in 8 of
11 (72%) pre-radiotherapy high-grade glioma patients, compared
with 1 of 8 (12%) in the post-radiotherapy cohort, demonstrating
the ability of the liquid biopsy to identify patients at risk of
recurrence/with high tumor burdens (88).
There is in addition a potential of the use of CTCs in the
identification of patients with a phenomenon known as pseudo-
progression – when the radiological features mimic tumor recur-
rence – but, in fact, the tumormay be undergoing a non-malignant
inflammatory change (2).
Cerebrospinal fluid (CSF) is also a potential source for glioma
CTCs biomarkers; however, this has not yet been evaluated in the
literature to date (2, 91, 92).
Conclusion
Detection of CTCs via so-called “liquid biopsies” carries enor-
mous clinical potential in CNS malignancies and requires urgent
further research. To date, studies in non-CNS malignancies,
particularly in breast cancer, show increasing reproducibility of
detection methods for these rare tumor cells in the circulation.
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However, no method has yet received full recommendation to use
in clinical practice, in part because of lack of a sufficient evidence
base regarding clinical utility.
In CNS malignancies, one of the main challenges is finding a
suitable biomarker for identification of these cells, because auto-
mated systems, such as the widely used Cell Search system, are
reliant onmarkers, such as EpCAM, which are not present in CNS
tumors. There are ongoing promising initial studies which have
identified CTCs in the peripheral blood of glioma patients using
physical separation techniques followed by IF for markers, such as
GFAP, nestin, and a telomerase promoter-based assay, or iCHIP
using the STEAM panel that consisted of SOX2, tubulin beta-3,
EGFR, A2B5, and c-Met.
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